How Trump’s GLP-1 agreements will impact benefit costs

Published 3 Min Read

GLP-1 medication and a tape measure.
Adobe Stock

  • Key Insight: Learn how employers are integrating GLP‑1 drugs into broader benefit strategies.
  • What’s at Stake: Rising drug access could shift insurer costs, retention strategies and benefit budgets.
  • Supporting Data: Trump administration deal targets cost reductions for GLP‑1s Wegovy and Zepbound.
  • Source: Bullets generated by AI with editorial review

A growing number of employers are offering weight loss drugs as part of their healthcare plans, while still promoting holistic programs and lifestyle changes as a long-term solution to physical fitness.

Jimmy Nesbitt
Reporter

Jimmy Nesbitt is a reporter at Employee Benefit News, where he covers the evolving landscape of workplace benefits, healthcare, retirement, financial wellness and related policy issues. His career … Read full bio


For reprint and licensing requests for this article, click here.


More From Employee Benefit News

Sign Up Form

Login Modal Form